Training grant in transfusion medicine

描述（由申请人提供）：这是一份更新的nssa申请（T32 HL69769），要求继续支持埃默里大学输血医学研究培训奖学金的有效和生产。输血医学的研究对该领域的未来至关重要，并对下游世界范围内输血和细胞疗法接受者的安全至关重要。埃默里输血和细胞治疗中心（CTCT）是美国最大、最全面的输血医学学术项目之一，致力于提供卓越的临床服务，出色的基础、转化和临床研究，以及对该领域未来领导者的临床和研究培训。T32博士后科学家培训计划是促进和履行埃默里CTCT使命的关键因素。如果获得资助，这项资助将继续为一名新的博士后CTCT研究实习生提供五年的工资支持，以参加一个为期两年的、高度结构化的、有指导的输血医学研究培训项目。我们的目标是满足输血医学基础、转化和跨学科研究培训的公认需求。需要这样的培训来培养输血、细胞治疗和移植研究方面的未来专家，以促进该专业的进一步发展和研究发展，并为其他研究和临床实践领域做出贡献。先前确定的项目优势包括：首席研究员/项目主任；组织小规模的培训计划，强调高质量的候选人和研究项目；高级教师的参与，具有强大的科学，资金和培训记录；提供具体的机制来教育研究员和外部评价培训方案；以及以前支持的研究员的学术成就。为了进一步强调该项目在培训博士后研究人员方面提供直接个人努力的承诺，教师导师仅限于那些有大量资金和在培训早期职业研究人员方面有良好记录的人。该项目最初于2004年获得资助，并于2009年获得续期。我们现在正在申请2014年开始的第二次续签。到目前为止，已有7名研究员完成了该项目，3名研究员正在培训中，1名研究员被指定开始。我们的T32研究员在论文出版、教师任命、拨款支持和指导委员会审查方面取得了很大的成功。项目主任非常感谢为支持这一重要培训工作而提供的资金，以及评审人员在评估本奖学金时自愿付出的时间和精力。

DESCRIPTION (provided by applicant): This is a renewal NRSA application (T32 HL69769) requesting continued support to maintain an effective and productive Transfusion Medicine Research Training Fellowship at Emory University. Research in transfusion medicine is vital to the future of the field and, downstream, to the safety of recipients of transfusion and cellular therapies worldwide. The Emory Center for Transfusion and Cellular Therapies (CTCT) is one of the largest, most comprehensive academic transfusion medicine programs in the nation and is dedicated to excellence in clinical service, outstanding basic, translational and clinical research and the clinical and research-based training of future leaders in the field. The T32 Post-Doctoral Scientist Training Program is a critical element in both contributing to, and fulfilling the missio of, the Emory CTCT. If funded, this grant would continue to provide salary support for one new post-doctoral CTCT Research Trainee per year for a 5-year period to participate in a 2-year, highly structured, mentored training program in transfusion medicine research. We aim to fill the acknowledged need for basic, translational, and interdisciplinary research training in transfusion medicine. Such training is needed to develop future specialists in transfusion, cell therapy and transplantation research in order to contribute to the further growth and research development of the specialty and its ability to contribute to other fields of research and clinical practice. Program strengths previously identified include: the Principal Investigator/Program Director; the organization of the training plan as a small-scale program emphasizing high-quality candidates and research projects; the involvement of senior faculty with strong scientific, funding, and training records; the provision of specific mechanisms for educating fellows and externally evaluating the training program; and the academic successes of previously-supported Fellows. To further underscore the program's commitment to providing direct personal effort in training post-doctoral research fellows, the faculty mentors have been limited to only those with significant funding and proven track records in training early-career investigators. The Program was initially funded in 2004 and renewed in 2009. We are now applying for a second renewal to commence in 2014. To date, 7 Fellows have completed the program, 3 Fellows are in the middle of training, and 1 Fellow is designated to start. Our T32 Fellows have been highly successful as evidenced by manuscript publications, faculty appointments, grant support, and Steering Committee review. The Program Director greatly appreciates the funding that has been provided to support this important training effort, and the time and effort volunteered by the reviewers in evaluating this Fellowship.